Official UK procurement notice
BH_NonClinical_Pharmacy_Car-T · UK public procurement notice
Authority: Barts Health NHS Trust (Central government)
What is being bought
Published requirement descriptionCAR-T therapy (Chimeric Antigen Receptor T-cell therapy) is a new personalised immunotherapy treatment where a patient’s T cells are genetically modified to target cancer cells.
The proposed contractor, Bristol Myers Squibb, will supply privately developed CAR T products
At the time of writing it is only offered at 8 sites across the UK.
The proposed contract is for 5 years with the option to extend by up to a further 5 years. The contract does not commit the Trust to place a minimum or any Order.
The price paid to the supplier with be capped at NICE / NHS England approved list prices.
The lotProcurement structure
single lot · no lot value publishedProcedure terms & legal framework
From the official record- Procedure method
- Direct award
- Legal basis
- UKPGA · 2023/54 Procurement Act 2023
- Notice status
- Awarded without competition
- Procurement threshold
- Unspecified in notice
- Regulatory regime
- Standard
- Commercial structure
- Stand-alone contract (no framework)
- Competition type
- Direct award (no call for competition)
- GPA / WTO covered
- Unspecified in notice
- Recurring procurement
- Unspecified in notice
- First published
- 26 Nov 2025, 09:46 GMT
- Last source update
- 26 Nov 2025, 09:46 GMT
- Authority reference
C402343- FTS notice number
2025/S 000-077086- Latest notice
- Transparency notice (UK5)
- Delivery area
- Not published
- Official registry OCID
ocds-h6vhtk-05e8d3Find a Tender
- Why no open competition
- Single Suppliers Intellectual Property Exclusive Rights
- Published justification
CAR-T therapy (Chimeric Antigen Receptor T-cell therapy) is a new personalised immunotherapy treatment where a patient’s T cells are genetically modified to target cancer cells.
The products can only be supplied by the the proposed contractor, Bristol Myers Squibb.
Notice history
2 events · 1 release on Find a Tender · since 26 Nov 2025- Transparency notice published26 Nov 2025, 09:46 GMTUK5
- Contract signature expected8 Dec 2025, 23:59 GMTscheduled
Commercial outcome & contract awards
Published awards, contracts and bid statistics, not a forecast| Awarded to | Value | Date | Status |
|---|---|---|---|
| Bristol Myers SquibbProvision of CAR-T therapy (Chimeric Antigen Receptor T-cell therapy) products8 Dec 2025 – 5 Dec 2030 · up to 7 Dec 2035Extensions: Option to extend contract by a further 5 years · Options: Extension option | £2,100,000 | — | Standstill |
Contracting authority & participating public bodies
Bidders & participating suppliers
1 commercial party on the notice- Bristol Myers SquibbAwarded supplier
Official documents & specifications (1)
Official links; attachments are not copiedNotices published for this procedure
- Transparency notice Transparency notice on Find a Tender